Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.

Competing Interests: Declaration of competing interest SAP, ESK, EAT, SK, AL, AM, HT, IC, AG, MWG, DAV, AA and FC have no competing interests. ME is a member of the advisory board for AMRA-Medical. SX has received research funding from Target RWE, restricted research funding from Axcella Health and consulting with Intercept Pharmaceuticals. CSM has been a shareholder of and reports grants through his institution and personal consulting fees from Coherus Incand Pangea Inc., reports grants through his institution and personal consulting fees from Novo Nordisk, reports personal consulting fees and in kind support with research reagents from Ansh -Ιnc., reports personal consulting fees from Genfit, P.E.S., Amgen, Intercept, Astra Zeneca, Aegerion and Regeneron, reports in kind support (meals during educational activities) from Amarin, Jansen, Boehringer Ingelheim and travel support and fees from TMIOA, the California Walnut Commission and the cardio metabolic health conference.